For discrete secondary outcomes, such as starting or increasing the dose of hypoglycemic medication and dis-continuing or decreasing the dose of hypoglycemic medication, we used the Fisher exact test (available at www.graphpad.com/quickcalcs/contingency1.cfm) for the 4 specified intergroup comparisons. Changes in anti-hypertensive and lipid-altering drugs were analyzed separately by using the same procedure as for changes in oral hypoglycemic drugs. In a post hoc analysis, we used the Fisher exact test to compare the numbers of participants with adverse events in all exercise groups combined versus those in the control group.